STOCK TITAN

Kura Oncology: BVF reports 7.5% beneficial stake

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Kura Oncology, Inc. (KURA) is the issuer whose common stock is covered by an amended beneficial-ownership report from several BVF-related reporting persons. As of September 30, 2026, Biotechnology Value Fund, L.P. reported 3,499,795 shares (3.9%), Biotechnology Value Fund II, L.P. reported 2,621,048 shares (2.9%), and Biotechnology Value Trading Fund OS LP reported 443,395 shares (0.5%). BVF GP Holdings LLC was attributed 6,120,843 shares (6.9%); BVF Partners L.P., BVF Inc. and Mark N. Lampert, a director and officer of BVF Inc., were each attributed 6,690,108 shares (7.5%).

The report describes shared voting and dispositive power and related-party relationships. It says deemed ownership by one reporting person is not itself an admission of ownership of shares held by another, and includes specific beneficial-ownership disclaimers from related entities and Mr. Lampert. The percentages use 88,960,619 shares outstanding as of August 7, 2026.

Biotechnology Value Fund, L.P. beneficial ownership 3,499,795 shares (3.9%) As of September 30, 2026
Biotechnology Value Fund II, L.P. beneficial ownership 2,621,048 shares (2.9%) As of September 30, 2026
Biotechnology Value Trading Fund OS LP beneficial ownership 443,395 shares (0.5%) As of September 30, 2026
BVF GP Holdings LLC deemed beneficial ownership 6,120,843 shares (6.9%) As of September 30, 2026
Deemed beneficial ownership attributed to each of BVF Partners L.P., BVF Inc. and Mark N. Lampert 6,690,108 shares (7.5%) As of September 30, 2026
KURA shares outstanding 88,960,619 shares As of August 7, 2026; denominator for the reported ownership percentages
beneficially owned regulatory
"BVF beneficially owned 3,499,795 Shares"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
shared voting power regulatory
"share voting and dispositive power over the Shares"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
shared dispositive power regulatory
"share voting and dispositive power over the Shares"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many KURA shares did each BVF fund report owning?

As of September 30, 2026, Biotechnology Value Fund, L.P. reported 3,499,795 shares (3.9%); Biotechnology Value Fund II, L.P. reported 2,621,048 shares (2.9%); and Biotechnology Value Trading Fund OS LP reported 443,395 shares (0.5%).

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google





50127T109

(CUSIP Number)
09/30/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



BIOTECHNOLOGY VALUE FUND L P
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:11/16/2026
BVF I GP LLC
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:11/16/2026
BIOTECHNOLOGY VALUE FUND II LP
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:11/16/2026
BVF II GP LLC
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:11/16/2026
Biotechnology Value Trading Fund OS LP
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:11/16/2026
BVF Partners OS Ltd.
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:11/16/2026
BVF GP HOLDINGS LLC
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:11/16/2026
BVF PARTNERS L P/IL
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:11/16/2026
BVF INC/IL
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:11/16/2026
LAMPERT MARK N
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert
Date:11/16/2026

Keep reading